Get the Stockscreener App
0.8132
3.13%
-0.0263
After Hours:
.83
0.0168
+2.07%
Atossa Therapeutics Inc stock is traded at $0.8132, with a volume of 429.61K.
It is down -3.13% in the last 24 hours and up +9.48% over the past month.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
See More
Previous Close:
$0.8395
Open:
$0.84
24h Volume:
429.61K
Relative Volume:
0.68
Market Cap:
$105.04M
Revenue:
-
Net Income/Loss:
$-26.91M
P/E Ratio:
-3.6964
EPS:
-0.22
Net Cash Flow:
$-19.57M
1W Performance:
-6.60%
1M Performance:
+9.48%
6M Performance:
-36.47%
1Y Performance:
-42.73%
1-Day Range:
$0.81
$0.8414
1-Week Range:
$0.81
$0.8971
52-Week Range:
$0.5526
$1.66
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
10202 5TH AVENUE NE, SEATTLE, WA
Compare ATOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.8132 | 112.47M | 0 | -26.91M | -19.57M | -0.22 |
|
ONC
Beigene Ltd Adr
|
240.41 | 25.57B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.10 | 111.79B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 39.90M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.85 | 65.28B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.31B | 0 | -153.72M | -103.81M | -2.00 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
Atossa Therapeutics Reports Q1 2025 Financial Results - TipRanks
Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock - Investing.com Australia
Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock By Investing.com - Investing.com Nigeria
Transcript : Atossa Therapeutics, Inc.Special Call - marketscreener.com
Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 - ACCESS Newswire
Atossa Therapeutics announces issuance of U.S. patent - MSN
Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 | ATOS Stock News - GuruFocus
Atossa CEO to Reveal Latest Phase 2 Results for Next-Gen Breast Cancer Drug in Exclusive Investor Webinar - Stock Titan
HC Wainwright Issues Optimistic Outlook for ATOS Earnings - Defense World
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? - Yahoo Finance
Atossa Therapeutics (ATOS) Reports Promising Phase 2 Trial Resul - GuruFocus
Atossa Therapeutics Announces Full Results from I?SPY?2 Endocrin - GuruFocus
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - StreetInsider
Wells Fargo & Company MN Has $68,000 Stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus
Atossa Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update - goSkagit
ATOSSA THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update | ATOS Stock News - GuruFocus
Barclays PLC Has $181,000 Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Monday - Defense World
Atossa Therapeutics reports progress in breast cancer treatments - MSN
Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - standard-journal.com
JPMorgan Chase & Co. Buys 211,654 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen F - GuruFocus
ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen Formulations | ATOS Stock News - GuruFocus
A look into Atossa Therapeutics Inc (ATOS)’s deeper side - Sete News
LPL Financial LLC Cuts Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics Inc (ATOS)’s results reveal risk - uspostnews.com
Atossa Therapeutics Inc (ATOS) rating initates by Maxim Group - knoxdaily.com
Sector Update: Health Care - marketscreener.com
Atossa Therapeutics (ATOS) Secures Patent for Key Breast Cancer Drug Formulations - GuruFocus
Atossa stock gains on U.S. patent win (ATOS:NASDAQ) - Seeking Alpha
Atossa Therapeutics Inc (ATOS) Stock: Navigating a Year of Volatility - investchronicle.com
Atossa Therapeutics Gets US Patent Covering (Z)-endoxifen Breast Cancer Treatment - marketscreener.com
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281 - GuruFocus
Atossa Therapeutics (ATOS) Secures Patent for Innovative Drug Fo - GuruFocus
Atossa Therapeutics secures new patent for breast cancer drug By Investing.com - Investing.com India
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio | ATOS Stock News - GuruFocus
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio - The Manila Times
Atossa Therapeutics secures new patent for breast cancer drug - Investing.com Australia
Major Patent Breakthrough: Atossa's Cancer Drug Portfolio Expands with 58 New Protected Formulations - Stock Titan
Atossa Therapeutics Proposes Potentially Groundbreaking Study Ai - GuruFocus
Atossa Therapeutics (ATOS) Launches SMART 2.0 Phase 3 Clinical S - GuruFocus
Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025 - The Manila Times
Revolutionary Breast Cancer Prevention Trial Could Reduce Risk by 20% in High-Risk Women - Stock Titan
Hilton (NYSE:HLT) Reports Sales Below Analyst Estimates In Q1 Earnings - The Globe and Mail
Renaissance Technologies LLC Boosts Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Stock Performance Spotlight: Atossa Therapeutics Inc (ATOS) Ends the Day at 0.73, Down by -0.73 - DWinneX
ATOS’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.70%
1.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):